No price history available.
Key financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | KRWm | 30,076,510 | 42,654,722 | 50,983,251 | 55,249,785 | 48,916,104 | 45,932,167 | N/A | N/A |
| Operating profit | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | KRWm | 512,634 | 3,669,787 | 1,845,363 | 1,337,812 | -690,854 | -1,819,449 | N/A | N/A |
| EPS reported | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
LG Chem, Ltd., alongside its various subsidiaries, operates as a diversified global entity with significant operations spanning petrochemicals, energy solutions, advanced materials, and life sciences, complemented by general and other commercial ventures. Its extensive international presence covers South Korea, China, the wider Asian region, the United States, Europe, and numerous other markets worldwide. The company's robust petrochemical division is a key producer of olefin derivatives such as ethylene, propylene, and butadiene from naphtha, alongside synthetic resins, components derived from olefins, and aromatic petrochemicals including benzene. Its comprehensive product range features polypropylene, bisphenol A, acrylonitrile butadiene styrenes (ABS), EP, polyvinyl chloride (PVC), plasticizers, acrylics, super absorbent polymers (SAPs), and synthetic rubber. In the energy sector, LG Chem specializes in manufacturing and supplying an extensive portfolio of batteries. This includes innovative IT and new application batteries for mobile phones and laptops, advanced automotive batteries specifically designed for electric vehicles, and high-capacity energy storage system (ESS) batteries. LG Chem's advanced materials segment is dedicated to developing and providing a variety of high-tech components. These encompass IT materials like polarizers, automotive materials, glass substrates, OLED films and materials, and battery materials. The segment also offers reverse osmosis (RO) membranes, semiconductor materials, and specialized display and battery materials used in LCD photoresist applications. Moreover, its life sciences arm delivers a spectrum of pharmaceutical and biotechnological products. Noteworthy offerings include human growth hormones such as Eutropin, diabetes medications like Zemiglo, bovine somatotropins (e.g., Boostin), various vaccines, and hyaluronic acid fillers, exemplified by YVORIE. This division also produces specialized fine chemical products, including the PYANCHOR herbicide for rice cultivation. Beyond these core industrial activities, the company is involved in the provision of crop protection products, seeds, fertilizers, and agricultural pesticides. It conducts pharmaceutical research, offers facility management and general cleaning services, and manufactures and sells adhesives and electronic parts. Additional business areas encompass the sale of pharmaceutical products and water processing membranes, agricultural pesticide licensing, and strategic investments in emerging venture companies. Established in 1947, LG Chem, Ltd. maintains its corporate headquarters in Seoul, South Korea.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
LG Chem, Ltd. (051915.KS)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
LG Chem, Ltd., alongside its various subsidiaries, operates as a diversified global entity with significant operations spanning petrochemicals, energy solutions, advanced materials, and life sciences, complemented by general and other commercial ventures. Its extensive international presence covers South Korea, China, the wider Asian region, the United States, Europe, and numerous other markets worldwide. The company's robust petrochemical division is a key producer of olefin derivatives such as ethylene, propylene, and butadiene from naphtha, alongside synthetic resins, components derived from olefins, and aromatic petrochemicals including benzene. Its comprehensive product range features polypropylene, bisphenol A, acrylonitrile butadiene styrenes (ABS), EP, polyvinyl chloride (PVC), plasticizers, acrylics, super absorbent polymers (SAPs), and synthetic rubber. In the energy sector, LG Chem specializes in manufacturing and supplying an extensive portfolio of batteries. This includes innovative IT and new application batteries for mobile phones and laptops, advanced automotive batteries specifically designed for electric vehicles, and high-capacity energy storage system (ESS) batteries. LG Chem's advanced materials segment is dedicated to developing and providing a variety of high-tech components. These encompass IT materials like polarizers, automotive materials, glass substrates, OLED films and materials, and battery materials. The segment also offers reverse osmosis (RO) membranes, semiconductor materials, and specialized display and battery materials used in LCD photoresist applications. Moreover, its life sciences arm delivers a spectrum of pharmaceutical and biotechnological products. Noteworthy offerings include human growth hormones such as Eutropin, diabetes medications like Zemiglo, bovine somatotropins (e.g., Boostin), various vaccines, and hyaluronic acid fillers, exemplified by YVORIE. This division also produces specialized fine chemical products, including the PYANCHOR herbicide for rice cultivation. Beyond these core industrial activities, the company is involved in the provision of crop protection products, seeds, fertilizers, and agricultural pesticides. It conducts pharmaceutical research, offers facility management and general cleaning services, and manufactures and sells adhesives and electronic parts. Additional business areas encompass the sale of pharmaceutical products and water processing membranes, agricultural pesticide licensing, and strategic investments in emerging venture companies. Established in 1947, LG Chem, Ltd. maintains its corporate headquarters in Seoul, South Korea.
